We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Employment Tribunal decision.
Orion Corporation T/A Orion Pharma (UK) Ltd are recalling specific batches as a precautionary measure due to an issue related to moulding defects in the bulk chambers where the inhalation powder is stored.
Following a comprehensive scientific safety review of the latest available data on the safety of pholcodine, together with advice from the independent Commission on Human Medicines, it has been concluded that the potential risks outweigh the benefits for these products.
Upper Tribunal Administrative Appeals Chamber decision by Judge Rowland on 15 February 2018.
The government has teamed up with independent pharmacies and Boots to launch a domestic abuse Ask for ANI codeword scheme.
First published during the 2019 to 2022 Johnson Conservative government
A joint enforcement notice warns all organisations offering Kenalog as a hayfever treatment to stop advertising it on social media or website advertising
Employment Tribunal Decision of Judge Davies on 3 March 2017.
Upper Tribunal Administrative Appeals Chamber decision of Judge Perez on 28 February 2020.
The maximum adult daily dose of hydroxyzine is now 100 mg. Do not prescribe hydroxyzine to people with a prolonged QT interval or risk factors for QT interval prolongation.
Use of aliskiren can cause angioedema, a rare and serious side effect, and or acute renal failure.
Tapentadol may increase seizure risk in patients taking other medicines that lower seizure threshold, for example, antidepressants and antipsychotics. Serotonin syndrome has also been reported when tapentadol is used in combination with serotoninergic antidepressants.
Upper Tribunal Administrative Appeals Chamber decision of Judge Poynter on 15 October 2020
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).